Literature DB >> 26473719

Burden of Comorbidity in Systemic Lupus Erythematosus in the UK, 1999-2012.

Frances Rees1, Michael Doherty2, Matthew Grainge2, Peter Lanyon1, Graham Davenport3, Weiya Zhang2.   

Abstract

OBJECTIVE: To estimate the comorbidity associated with systemic lupus erythematosus (SLE) in the UK during 1999-2012.
METHODS: A retrospective cohort study using the UK Clinical Practice Research Datalink was conducted. Prevalent cases of SLE were matched by age, sex, and practice to 4 controls. The incidence of cardiovascular disease (CVD), stroke, end-stage renal failure (ESRF), cancer, osteoporosis, and infection were calculated per 1,000 person-years during the study period and compared to controls using Poisson regression to obtain incidence rate ratios (IRRs). IRRs were adjusted for baseline age, sex, body mass index, smoking status, alcohol intake, hypertension, hyperlipidemia, Charlson Index scores, and prednisolone use. Age- and sex-specific incidence rates were calculated.
RESULTS: When comparing the 7,732 prevalent cases of SLE with 28,079 matched controls, the unadjusted IRR was 1.98 (95% confidence interval [95% CI] 1.69-2.31) for CVD, 1.81 (95% CI 1.49-2.19) for stroke, 7.81 (95% CI 4.68-13.05) for ESRF, 1.28 (95% CI 1.17-1.40) for cancer, 2.53 (95% CI 2.27-2.82) for osteoporosis, and 1.49 (95% CI 1.40-1.58) for infection. After adjustment, the rates remained significantly higher in cases. Men with SLE had higher rates of CVD, stroke, and cancer, whereas women had higher rates of infection and osteoporosis. Those at younger ages were at the greatest relative risk compared with controls. Cases had significantly higher Charlson Index scores at baseline.
CONCLUSION: People with SLE in the UK have a greater burden of comorbidity and are more likely to develop CVD, stroke, ESRF, cancer, osteoporosis, and infection than people of the same age and sex.
© 2016, American College of Rheumatology.

Entities:  

Mesh:

Year:  2016        PMID: 26473719     DOI: 10.1002/acr.22751

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  18 in total

1.  Systemic lupus erythematosus.

Authors:  Maliha F Shaikh; Natasha Jordan; David P D'Cruz
Journal:  Clin Med (Lond)       Date:  2017-02       Impact factor: 2.659

Review 2.  Inflammatory diseases and bone fragility.

Authors:  K Briot; P Geusens; I Em Bultink; W F Lems; C Roux
Journal:  Osteoporos Int       Date:  2017-09-15       Impact factor: 4.507

3.  Risk of pancreatic cancer in patients with systemic lupus erythematosus: a meta-analysis.

Authors:  Min-Seok Seo; Jina Yeo; In Cheol Hwang; Jae-Yong Shim
Journal:  Clin Rheumatol       Date:  2019-07-03       Impact factor: 2.980

Review 4.  Autoimmune-mediated renal disease and hypertension.

Authors:  Erika I Boesen; Rahul M Kakalij
Journal:  Clin Sci (Lond)       Date:  2021-09-17       Impact factor: 6.876

5.  High risk of depression, anxiety, and an unfavorable complex comorbidity profile is associated with SLE: a nationwide patient-level study.

Authors:  Fruzsina Kósa; Péter Kunovszki; Judit Gimesi-Országh; Melinda Kedves; Melinda Szabó; Chetan S Karyekar; György Nagy
Journal:  Arthritis Res Ther       Date:  2022-05-19       Impact factor: 5.606

6.  Association between systemic lupus erythematosus and lung cancer: results from a pool of cohort studies and Mendelian randomization analysis.

Authors:  Haoxin Peng; Caichen Li; Xiangrong Wu; Yaokai Wen; Jinsheng Lin; Hengrui Liang; Ran Zhong; Jun Liu; Jianxing He; Wenhua Liang
Journal:  J Thorac Dis       Date:  2020-10       Impact factor: 3.005

Review 7.  Bone Disease in Connective Tissue Disease/Systemic Lupus Erythematosus.

Authors:  Irene E M Bultink
Journal:  Calcif Tissue Int       Date:  2017-09-12       Impact factor: 4.333

Review 8.  Systemic Lupus Erythematosus in Primary Care: An Update and Practical Messages for the General Practitioner.

Authors:  Irini Gergianaki; George Bertsias
Journal:  Front Med (Lausanne)       Date:  2018-05-29

9.  Dosage and Duration of Methylprednisolone Therapy Affect the Occurrence of Cushing Habitus in Patients with Systemic Lupus Erythematosus.

Authors:  Didi Permana; Melisa I Barliana; Laniyati Hamijoyo
Journal:  J Pharm Bioallied Sci       Date:  2019-12-30

Review 10.  Management of glucocorticoid-related osteoporotic vertebral fracture.

Authors:  Stella Pui Yan Wong; Chi Chiu Mok
Journal:  Osteoporos Sarcopenia       Date:  2020-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.